8-K: Reviva Reports Q3 2025 Results, Brilaroxazine Advances

Reviva Pharmaceuticals reported a reduced net loss in Q3 2025 and provided updates on its lead drug candidate, brilaroxazine, including plans for an FDA pre-NDA meeting and potential NDA submission for schizophrenia.

Summary

• Net loss for the three months ended September 30, 2025, was approximately $4.0 million, or $0.06 per share, a significant improvement compared to a net loss of approximately $8.4 million, or $0.25 per share, for the same period in 2024.
• Cash and cash equivalents totaled approximately $13.2 million as of September 30, 2025, slightly down from approximately $13.5 million as of December 31, 2024.
• A pre-NDA meeting with the FDA to discuss brilaroxazine's path to approval for schizophrenia is planned for Q4 2025.
• Potential NDA submission for the schizophrenia indication is targeted for Q2 2026.
• A European patent (EP3749324) was granted, covering the use of brilaroxazine for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF), adding to existing patent protection in key global markets.
• The company announced a positive full dataset and successful completion of its Phase 3 RECOVER open-label extension (OLE) 1-year study, evaluating the long-term safety, tolerability, and efficacy of brilaroxazine in patients with schizophrenia (N=446).
• The OLE study demonstrated robust broad-spectrum efficacy sustained over 1-year, including a PANSS total score reduction of 18.1, negative symptoms reduction of 4.4, and CGI-S improvement of -0.8 (a 1-point improvement in 78% of patients).
• The OLE study showed a favorable safety profile with no clinically meaningful changes in movement disorder scales, benign weight gain (~1.5 kg), favorable and consistent improvement in lipid profile, stable blood sugar levels, no hormonal imbalance, and no significant cardiac or gastrointestinal side effects.
• A public equity offering was completed, raising gross proceeds of $9.0 million before deducting placement agent fees and other offering expenses.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for brilaroxazine, significant progress towards regulatory approval, and improved financial performance with a reduced net loss. The successful equity raise also strengthens the balance sheet. While still operating at a loss, the clinical and regulatory momentum is highly favorable.

Positives

• Net loss significantly decreased to $4.0 million in Q3 2025 from $8.4 million in Q3 2024, indicating improved financial performance.
• Successful completion of the Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine in schizophrenia, demonstrating broad-spectrum, durable efficacy and a favorable safety profile.
• A European patent was granted for brilaroxazine's use in pulmonary fibrosis, strengthening intellectual property and expanding potential indications.
• Clear progress towards FDA approval with a planned pre-NDA meeting in Q4 2025 and targeted NDA submission in Q2 2026 for schizophrenia.
• A public equity offering raised $9.0 million in gross proceeds, bolstering the company's cash position.

Negatives

• Cash and cash equivalents slightly decreased to $13.2 million as of September 30, 2025, from $13.5 million at December 31, 2024, indicating ongoing cash burn.
• Research and development expenses, while lower than the prior year, still represent a significant outflow ($2.1 million for Q3 2025).
• The company continues to operate at a net loss.

Risks

• Forward-looking statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different.
• Such factors include those set forth in the company's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings from time to time with the Securities and Exchange Commission.
• Prospective investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the press release.

Future Outlook

Reviva Pharmaceuticals plans a pre-NDA meeting with the FDA in Q4 2025 to discuss brilaroxazine's path to approval for schizophrenia, targeting a potential NDA submission in Q2 2026. The company also expects to submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis by H2 2026 and is actively pursuing partnership opportunities for pipeline development.

Management Comments

• "With the comprehensive clinical and non-clinical data package in hand, we believe brilaroxazine is strongly positioned to meet New Drug Application (NDA) filing requirements and advance toward potential registration for schizophrenia."
• "The consistent body of evidence for brilaroxazine, from early clinical studies through long-term extension studies, continues to demonstrate broad-spectrum, durable efficacy, a favorable safety profile, and strong long-term adherence with once-daily dosing."
• "We are preparing for a pre-NDA meeting with the Food and Drug Administration (FDA) in the fourth quarter of the year and continue to target a potential NDA submission in the second quarter of 2026."
• "We believe brilaroxazine's differentiated clinical profile has the potential to redefine treatment expectations in schizophrenia and significantly improve patient outcomes worldwide."

Industry Context

The advancement of brilaroxazine for schizophrenia, a central nervous system (CNS) disorder with significant unmet medical needs, positions Reviva within a competitive but high-demand therapeutic area. The focus on broad-spectrum efficacy, favorable safety, and once-daily dosing aims to differentiate it from existing antipsychotics, which often have significant side effects and adherence challenges. The additional patent for pulmonary fibrosis also indicates a strategy to diversify the drug's potential applications, tapping into another area with high unmet need, similar to how other biopharma companies seek to maximize asset value across multiple indications.

Comparison to Industry Standards

• The reported benign weight gain of ~1.5 kg over 52 weeks for brilaroxazine compares favorably to many atypical antipsychotics, which are often associated with significant weight gain (e.g., olanzapine, clozapine can lead to 5-10 kg or more in the first year), a major factor in patient non-adherence and metabolic complications.
• The favorable and consistent improvement in lipid profile and stable blood sugar levels for brilaroxazine are notable, as many current antipsychotics (e.g., risperidone, quetiapine) are known to induce dyslipidemia and hyperglycemia, increasing cardiovascular risk.
• No clinically meaningful changes in movement disorder scales (akathisia, extrapyramidal symptoms) for brilaroxazine is a positive differentiator, as these side effects are common with many antipsychotics (e.g., haloperidol, even some atypicals like risperidone) and significantly impact quality of life and adherence.
• The reduction of elevated prolactin levels to normal or near normal is an advantage, as hyperprolactinemia is a common side effect of several antipsychotics (e.g., risperidone, paliperidone), leading to sexual dysfunction and other endocrine issues.
• The 35% discontinuation rate after 1-year for pooled doses of brilaroxazine, while not directly comparable without context of other OLE studies, generally aligns with or is potentially better than real-world adherence rates for some antipsychotics, which can be as low as 50% within the first year due to side effects or lack of efficacy.

Stakeholder Impact

• Shareholders: Potential positive impact due to advancement of lead drug candidate towards approval, strengthening of patent portfolio, and reduced net loss. The equity offering diluted existing shares but provided necessary capital.
• Patients (schizophrenia): Potential for a new treatment option with broad-spectrum efficacy, favorable safety profile, and once-daily dosing, which could improve outcomes and adherence.
• Patients (pulmonary fibrosis): Future potential for a new treatment option if brilaroxazine is developed for this indication, supported by Orphan Drug Designation and new patent.
• Investment Professionals: Provides clear milestones and positive clinical data for evaluation.

Next Steps

• Planned pre-NDA meeting with FDA to discuss brilaroxazine's path to approval in Q4 2025.
• Potential NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026.
• Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by H2-2026.
• Pursuing partnership opportunities for the development of the pipeline.
• Scheduled to present a late-breaking poster presentation on anti-inflammatory biomarker data for brilaroxazine at the Society for Neuroscience Annual Meeting (November 15-19, 2025).

Key Dates

Recommendation

The filing demonstrates significant progress for Reviva's lead asset, brilaroxazine, with robust positive Phase 3 OLE data for schizophrenia, a clear regulatory path with a pre-NDA meeting scheduled, and a targeted NDA submission. The favorable safety and efficacy profile, particularly regarding weight gain and metabolic parameters, positions brilaroxazine as a potentially differentiated treatment in a large market. The European patent for pulmonary fibrosis expands future optionality. While the company is still pre-revenue and burning cash, the reduced net loss and successful capital raise provide runway. The strong clinical data and imminent regulatory milestones significantly de-risk the asset and present a compelling investment opportunity for long-term growth.

Keywords

Reviva Pharmaceuticals, RVPH, brilaroxazine, schizophrenia, pulmonary fibrosis, IPF, FDA, NDA, Phase 3, RECOVER study, Q3 2025 earnings, biopharmaceutical, CNS, inflammatory diseases, cardiometabolic diseases, patent protection, Orphan Drug Designation